All the news Showing 10 of 842 articlesGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources New and experimental treatments for hepatitis B NASVAC therapeutic vaccine may lead to functional cure of hepatitis B Liz Highleyman / 17 November 2020 NASVAC, an experimental therapeutic vaccine that targets two different hepatitis B virus (HBV) antigens, led to a reduction in hepatitis B surface antigen levels and several study participants achieved a functional cure after ... Coronavirus Fatty liver greatly increases vulnerability to COVID-19 in obese people Keith Alcorn / 16 November 2020 Fatty liver disease combined with obesity places people at much higher risk of severe COVID-19, analysis of British people who tested positive for SARS-CoV-2 shows. Obesity alone did not increase the risk ... Coronavirus Which people with chronic liver disease have higher COVID-19 risks? Keith Alcorn / 16 November 2020 Decompensated cirrhosis, alcoholic liver disease and hepatocellular carcinoma each raise the risk of death and severe illness from COVID-19 among people with chronic liver disease, but other liver conditions do not, a US ... Treatment for people who use drugs Peers of drug users play key roles in hepatitis C treatment decision-making Keith Alcorn / 04 November 2020 Peers are important sources of information about hepatitis C treatment and may be the most persuasive advocates for engaging with treatment and care among drug users, a study in Melbourne, Australia, shows. People ... Experimental treatments for NASH/NAFLD Cotadutide improves metabolic and liver biomarkers in people with NAFLD and diabetes Liz Highleyman / 26 October 2020 Cotadutide, an experimental therapy that alters glucose and lipid metabolism, led to weight loss and improvements in metabolic, cardiovascular and liver fibrosis biomarkers in overweight people with diabetes and fatty liver disease, but ... Experimental treatments for NASH/NAFLD Experimental NASH treatments: Gilead candidates miss primary endpoint but show some benefits Liz Highleyman / 20 October 2020 Combinations of experimental drugs for non-alcoholic steatohepatitis (NASH) failed to meet a study's primary endpoint by significantly improving liver fibrosis without worsening NASH, but one combination in particular – firsocostat plus ... Hepatitis C elimination Test and treat reduces hepatitis C by 83% in Melbourne gay men with HIV Keith Alcorn / 13 October 2020 Testing and treatment for hepatitis C in gay and bisexual men with HIV in Melbourne reduced the prevalence of the infection by 83% between 2012 and 2019, Australian researchers report ... NAFLD Fatty liver disease common in people living with HIV and hepatitis B Keith Alcorn / 30 September 2020 Around one in three people with HIV and hepatitis B had fatty liver disease and one in ten had liver damage, US researchers from the Hepatitis B Research Network report in Clinical ... NAFLD Diabetes raises the risk of liver damage in people with HIV Keith Alcorn / 21 September 2020 Almost half of people with HIV with unexplained liver enzyme elevations or other abnormal liver markers had non-alcoholic steatohepatitis (NASH) and 39 of 116 had stage F3 or F4 fibrosis, and advanced ... Hepatocellular carcinoma (HCC) Models can help predict liver cancer in people cured of hepatitis C Liz Highleyman / 17 September 2020 Three new methods using readily available clinical parameters can help predict who will develop hepatocellular carcinoma (HCC) after achieving sustained virological response to hepatitis C treatment, according to studies presented at the recent 2020 Digital ... ← Prev12345...85Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Noticeboard Email bulletins News feeds